Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

NCT05008666 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Safety and Efficacy

Interventions

DRUG: Sintilimab
DRUG: Chidamide
DRUG: Azacitidine
DRUG: L-DEP

Sponsor

Sun Yat-sen University